AMJEVITA

PeakmAb

adalimumab-atto

Amgen
BLAINJECTIONINJECTABLE
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Tumor Necrosis Factor Receptor Blocking Activity

Pharmacologic Class:

Tumor Necrosis Factor Blocker

Company
Amgen
Amgen
THOUSAND OAKS, CA
1215 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers